{‘She possesses zero expertise’: this US scientific establishment girds for Dr. Høeg's tenure at the FDA.

As the United States continues making historic revisions to its vaccination schedules, a particular individual appears somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who first made her name by casting doubt on coronavirus vaccinations throughout the pandemic and has concentrated on potential fatalities following Covid immunization in her short position at the FDA.

Proposed Shifts to Childhood Vaccine Schedule

Public health authorities were set to reveal radical changes to the pediatric vaccination calendar in December, synchronizing the US with the Danish national calendar, it is understood – a substantial departure that would put the US at odds with much of the global community with no evidence for improved outcomes. This reveal has been postponed until the new year.

Instead of the director of the vaccine center, Tracy Beth Høeg is set to address the audience at the meeting. She was recently named interim head of the FDA’s drug evaluation center, the fifth appointee to head the center this year.

A New Direction at the Regulatory Body

This interim role might represent a strengthened alliance between the drug and biologics centers as Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it suggests a greater focus upon dismantling previously authorized vaccines at the FDA.

Dr. Høeg has often pushed for halting certain pediatric shot schedules in the US to become more similar to Denmark, a nation with universal health coverage and a population about the population of the state of Wisconsin.

So far statements, she has kept her attention on vaccination policy – usually the purview of Prasad, head of the FDA’s vaccine center – rather than pharmaceutical oversight.

Doubts Over Qualifications

Høeg has little discernible experience in medication creation, approval processes or leadership, which has been standard for past directors of the biologics center. She has served at the FDA as a senior adviser to the agency head and the vaccine center since earlier this year.

“She appears not to have any of the qualifications” for leading the drug-regulation department, stated Dr. Jonathan Howard. “She has not conducted a scientific study. She lacks experience in running a sizeable institution. She has no expertise in industry regulation.”

Previous commissioners of CBER would “grasp laws and regulations and the underlying principles of medication creation”, noted a former acting FDA commissioner. “Frankly, she doesn’t have the type of experience that former directors who led the center have had.”

CDER has an vast range of responsibilities at the FDA, Woodcock stated.

“Everybody just zeroes in on the novel medication approvals, but the generic program authorizes numerous generic medications. There’s a biosimilars division, non-prescription drug unit and so forth, and all of those need to be supervised,” Woodcock noted. “The thing you neglect, that is the part that I always told people is going to come back to haunt you.”

Additionally, a substantial management element to the role, which supervises over 5,000 personnel. “It’s a enormous administrative position, if you do it right,” Woodcock added.

Response and Disputed Policies

In response to inquiries about Høeg’s credentials and whether this selection represents greater collaboration among FDA leaders on immunizations, a spokesperson stated that the “concerns stem from inaccurate premises”.

“Her experience aligns with the duties of her role,” the spokesperson stated, noting the period Dr. Høeg spent counseling the FDA commissioner on “medication safety and approval science, including computational safety modeling and vaccine surveillance”.

In her interim role, Høeg assumes responsibility for the agency head's new priority voucher program, a controversial one-day medication authorization process that allegedly worried her predecessors. “By what process are these medications being picked for this expedited pathway? Who takes the calls?” Dr. Howard asked. “There’s a lot of lack of transparency going on at the agency right now.”

Overall, he stated, “the Food and Drug Administration looks to be trending towards laxer oversight of all drugs, with the exception of shots.”

Documented Track Record on Vaccines

Concerning immunizations, Høeg has a more documented, if troubling, history, critics have noted. She released a research paper using non-validated public submissions to estimate the rate of myocarditis after COVID-19 immunization. She advised the state of Florida top health official Joseph Ladapo, who reportedly have changed statistics to suggest COVID-19 vaccines are more dangerous than they are.

Among her “desired changes” for the current federal leadership included revising regulations for recently developed shots and halting “non-essential” immunizations, she stated following the vote on a podcast. At the agency, Høeg has according to sources floated the idea of preventing adolescent males from receiving Covid vaccinations.

“She’s an thorough dogmatist who starts off with her preconceived notions and works backwards to retrofit the evidence in a very misleading, fraudulent fashion,” Howard said.

Taking Control and a “Push for Payback”

Dr. Høeg became part of fellow contrarians, {like|